All over the U.S., people taking PrEP are being urged to go with Descovy instead of Truvada. Our HIV prevention expert answers the question: Is it worthwhile to make the switch?
“PrEP is our number-one priority, but it’s not easy. There’s a lot of misconceptions and misinformation out there.”
Amidst skyrocketing housing costs and historic racial segregation, APLA expands its work to Black and brown neighborhoods.
Ending the HIV Epidemic Is a Team Effort. The New York City and State Health Departments Discuss Their Combined Work
Johanne Morne, M.S., and Oni Blackstock, M.D., sat down with TheBody to discuss their successes and their work to close the disparities gap.
Baltimore has made a lot of progress when it comes to its HIV epidemic, but black gay and bisexual men aren’t seeing the same downturn in diagnosis rates.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
The Centers for Disease Control and Prevention (CDC) finds that new HIV diagnoses have plateaued.
What can other cities learn from it? And how can the city close its final gap?
Ready, Set, PrEP expands access to pre-exposure prophylaxis meds, but it doesn't cover other costs.
Dec. 5, 2019: The value of pre-treatment drug resistance testing; resistance rates among viremic Americans; persistent pneumonia incidence among people with HIV; mixed HIV prevention results for the U.S. National HIV Strategy.